Biotechnology company developing therapies to reverse atherosclerosis and regenerate the thymus gland. Cholesterol Degrading Platform (CDP) achieved a 48% reversal of aortic plaque obstruction in a single preclinical treatment. Raised $2.15M seed led by Jim Mellon. *Catalogued by Claude* On this page you can view the company profile, browse linked jobs, products, posts, and ventures, inspect verification and contact details, follow related identity links.